Evidence map›Paper›PMID 32678710›Full record

ArticleJCO global oncology2020

Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey.

Neslihan Cabioğlu, Sibel Özkan Gürdal, Arda Kayhan, Nilüfer Özaydın, Cennet Şahin, Ömür Can, Beyza Özçınar, Gönül Aykuter, Gülçin Vatandaş, Erkin Aribal and 1 more

Open access · goldAbstract read
In one paragraph

Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Neslihan CabioğluDepartment of Surgery, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
Sibel Özkan GürdalDepartment of Surgery, Namık Kemal University, Faculty of Medicine, Tekirdag, Turkey.
Arda KayhanDepartment of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey.
Nilüfer ÖzaydınDepartment of Public Health, Marmara University, Faculty of Medicine, Istanbul, Turkey.
Cennet ŞahinDepartment of Radiology, Şişli Etfal Research and Teaching Hospital, Istanbul, Turkey.
Ömür CanMEMEDER Screening Center, Bahçeşehir, Istanbul, Turkey.
Beyza ÖzçınarDepartment of Surgery, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
Gönül AykuterMEMEDER Screening Center, Bahçeşehir, Istanbul, Turkey.
Gülçin VatandaşMEMEDER Screening Center, Bahçeşehir, Istanbul, Turkey.
Erkin AribalDepartment of Radiology, Acıbadem University, Faculty of Medicine, Istanbul, Turkey.
Vahit ÖzmenDepartment of Surgery, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
Bahçeşehir University · TRIstanbul University · TRAcıbadem University · TRErzincan University · TRMarmara University · TRNamık Kemal University · TRŞişli Etfal Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period.

methodsBetween 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer.

resultsIn 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1%

conclusionOur findings suggest the majority of screen-detected breast cancers exhibited a luminal A subtype profile with an excellent prognosis. However, interval cancers were more likely to have aggressive subtypes such as luminal B subtype or triple-negative cancers associated with a poor prognosis requiring other preventive strategies.

Indexed as

Breast NeoplasmsBiomarkers, TumorEarly Detection of CancerFemaleHumansPrognosisTurkeyBiomarkers, Tumor

Identifiers

PMID32678710
PMCPMC7392766
OpenAlexW3042719765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.